Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Asset Purchase Agreement and Earnout Agreement with the Biofrontera Group to acquire U.S. rights to Ameluz and RhodoLED, with earnout payments of 12% or 15% of U.S. Ameluz revenues
Issuance of 3,019 shares of Series D Preferred Stock to the Biofrontera Group in exchange for the U.S. Rights
Right of Biofrontera AG to appoint one director to the Board under the Strategic Transaction; Dr. Lanckriet serves as its designee
Second Amended and Restated Ameluz License and Supply Agreement under which the Company held an exclusive license to market Ameluz and RhodoLED in the U.S. and purchased licensed products from Biofrontera Pharma
Purchases of previously licensed Ameluz and RhodoLED products from Biofrontera Pharma, recorded in inventories
Earnout expense recorded in cost of revenues related to U.S. Ameluz sales under the Strategic Transaction
Payments to the Biofrontera Group for expenses related to U.S. product sales, including production, quality control, pharmacovigilance, regulatory activities and rent
Participation in the Preferred Offering under the Preferred Purchase Agreement for Series B-1 Preferred Stock and 2024 Preferred Warrants
Convertible Notes Offering of 10.0% Senior Secured Convertible Notes to certain principal stockholders
Employment as Director of Clinical Trial Management at wholly owned subsidiary Biofrontera Discovery GmbH, with total compensation in 2025
Loading...
